MedPath

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Phase 3
Active, not recruiting
Conditions
Gastric Neoplasms
Gastroesophageal Adenocarcinoma
Esophageal Adenocarcinoma
Interventions
Registration Number
NCT05152147
Lead Sponsor
Jazz Pharmaceuticals
Brief Summary

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.

The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
920
Inclusion Criteria
  • Histologically confirmed unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Subjects with esophageal adenocarcinoma must not be eligible for combined chemoradiotherapy at the time of enrollment
  • Assessable (measurable or non-measurable) disease as defined by RECIST 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, assessed within 3 days prior to randomization
  • Adequate organ function
  • Left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA)
Exclusion Criteria
  • Prior treatment with a HER2-targeted agent, with the exception of subjects who received HER2-targeted treatment for breast cancer > 5 years prior to initial diagnosis of GEA
  • Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Prior treatment with systemic antineoplastic therapy or intraperitoneal chemotherapy for unresectable locally advanced, recurrent or metastatic GEA
  • Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks prior to randomization. Stable, treated brain metastases are allowed (defined as subjects who are completely off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks prior to randomization)
  • Known history of or ongoing leptomeningeal disease (LMD)
  • Known additional malignancy that is not considered cured or that has required treatment within the past 3 years
  • Known active hepatitis
  • Any history of human immunodeficiency virus (HIV) infection
  • Known SARS-CoV-2 infection; subjects with prior infection that has resolved per local institutions' requirements and screening guidance are eligible
  • QTc Fridericia (QTcF) > 470 ms
  • Clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm COxaliplatinZanidatamab and tislelizumab plus physician's choice of CAPOX or FP
Arm CCisplatinZanidatamab and tislelizumab plus physician's choice of CAPOX or FP
Arm C5-FluorouracilZanidatamab and tislelizumab plus physician's choice of CAPOX or FP
Arm BZanidatamabZanidatamab plus physician's choice of CAPOX or FP
Arm ATrastuzumabTrastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)
Arm ACapecitabineTrastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)
Arm AOxaliplatinTrastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)
Arm ACisplatinTrastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)
Arm A5-FluorouracilTrastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)
Arm BCapecitabineZanidatamab plus physician's choice of CAPOX or FP
Arm BOxaliplatinZanidatamab plus physician's choice of CAPOX or FP
Arm BCisplatinZanidatamab plus physician's choice of CAPOX or FP
Arm B5-FluorouracilZanidatamab plus physician's choice of CAPOX or FP
Arm CZanidatamabZanidatamab and tislelizumab plus physician's choice of CAPOX or FP
Arm CTislelizumabZanidatamab and tislelizumab plus physician's choice of CAPOX or FP
Arm CCapecitabineZanidatamab and tislelizumab plus physician's choice of CAPOX or FP
Primary Outcome Measures
NameTimeMethod
Progression-free survival (PFS) by BICRUp to 2.5 years

The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause

Overall survivalUp to 3.5 years

The time from randomization to death due to any cause

Secondary Outcome Measures
NameTimeMethod
Confirmed objective response rate (ORR) by BICRUp to 2.5 years

Number of patients who achieved a best overall response of complete response (CR) or (PR) as determined per RECIST 1.1 as assessed by BICR

Duration of response (DOR) by BICRUp to 2.5 years

The time from the first objective response (CR or PR) per BICR to documented progressive disease per RECIST 1.1 as assessed by BICR or death from any cause

PFS per Investigator assessmentUp to 2.5 years

The time from randomization to the date of documented disease progression (per RECIST 1.1) as assessed by Investigator or death from any cause

Confirmed ORR per Investigator assessmentUp to 2.5 years

Number of patients who achieved a best overall response of CR or PR as determined per RECIST 1.1 as assessed by Investigator

DOR per Investigator assessmentUp to 2.5 years

The time from the first objective response (CR or PR) per Investigator to documented progressive disease per RECIST 1.1 as assessed by Investigator or death from any cause

Assessment of Contribution of Components based on Progression-free Survival (PFS) by BICRUp to 2.5 years

The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause

Assessment of Contribution of Components based on Overall SurvivalUp to 3.5 years

The time from randomization to death due to any cause

Incidence of adverse eventsUp to 2 years

Number of subjects who experienced adverse events or serious adverse events

Incidence of clinical laboratory abnormalitiesUp to 2 years

Number of patients who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

Health-related quality of life (HRQoL) as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (core cancer questionnaire) C30 (QLQ-C30)Up to 2.5 years

Changes from baseline in the EORTC QLQ-C30 scores

HRQoL as assessed by the EORTC Quality of Life Questionnaire (oesophago-gastric module) OG25 (QLQ-OG25)Up to 2.5 years

Changes from baseline in the EORTC QLQ-OG25 scores

HRQoL as assessed by the EuroQol 5-dimensions 5-levels (EQ-5D-5L) questionnaireUp to 2.5 years

Changes from baseline in the EORTC EQ-5D-5L questionnaire scores

Serum concentration of zanidatamab and tislelizumabUp to 2 years
Incidence of anti-drug antibodies (ADAs)Up to 2 years

Number of patients who develop ADAs

Trial Locations

Locations (226)

Hospital de Gastroenterología Dr Bonorino Udaondo

🇦🇷

Buenos Aires, Argentina

Instituto de Investigaciones Metabólicas - IDIM

🇦🇷

Buenos Aires, Argentina

Hospital Italiano de Buenos Aires

🇦🇷

Buenos Aires, Argentina

Fundación Centro de Medicina Nuclear y Molecular ER

🇦🇷

Córdoba, Argentina

Centro Médico Privado CEMAIC

🇦🇷

Córdoba, Argentina

Centro de Investigación Pergamino S.A.

🇦🇷

Pergamino, Argentina

Centro de Investigación Clínica - Clínica Viedma

🇦🇷

Viedma, Argentina

Flinders Medical Centre

🇦🇺

Bedford Park, Australia

Austin Health

🇦🇺

Heidelberg, Australia

Liverpool Hospital

🇦🇺

Liverpool, Australia

Scroll for more (216 remaining)
Hospital de Gastroenterología Dr Bonorino Udaondo
🇦🇷Buenos Aires, Argentina

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.